Organogenesis (NASDAQ:ORGO) Rating Lowered to Strong Sell at Wall Street Zen

Organogenesis (NASDAQ:ORGO) was downgraded by analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research report issued on Saturday, Wall Street Zen reports.

Other equities research analysts also recently issued research reports about the stock. Weiss Ratings downgraded shares of Organogenesis from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, October 19th. Truist Financial cut their target price on shares of Organogenesis from $3.00 to $2.00 and set a “hold” rating on the stock in a report on Friday, August 7th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Organogenesis currently has a consensus rating of “Reduce” and an average target price of $4.33.

Organogenesis Price Performance

Organogenesis stock opened at $0.81 on Friday. The firm has a market capitalization of $104.64 million, a P/E ratio of -0.67 and a beta of 1.48. Organogenesis has a 1 year low of $0.73 and a 1 year high of $7.08. The business has a 50-day moving average of $1.26 and a 200-day moving average of $2.31. The company has a current ratio of 3.32, a quick ratio of 2.76 and a debt-to-equity ratio of 0.09.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). Organogenesis had a negative net margin of 39.34% and a negative return on equity of 55.28%. The firm had revenue of $45.46 million during the quarter, compared to analyst estimates of $52.10 million.

Institutional Investors Weigh In On Organogenesis

Several large investors have recently modified their holdings of the business. Waverly Advisors LLC bought a new stake in Organogenesis during the 2nd quarter worth approximately $25,000. Sequoia Financial Advisors LLC acquired a new stake in Organogenesis during the 2nd quarter worth approximately $33,000. Pallas Capital Advisors LLC acquired a new stake in Organogenesis during the 2nd quarter worth approximately $37,000. The Manufacturers Life Insurance Company acquired a new stake in Organogenesis during the 2nd quarter worth approximately $44,000. Finally, Capital Square LLC bought a new position in Organogenesis in the second quarter valued at approximately $45,000. 49.57% of the stock is currently owned by institutional investors.

Key Organogenesis News

Here are the key news stories impacting Organogenesis this week:

• Positive Sentiment: Management expects to reduce annual operating expenses by approximately $45 million, which could help lower costs. Third-quarter net product revenue also rose 6% from the prior quarter, signaling some sequential recovery. Article: Organogenesis: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: The earnings call was characterized as showing signs of recovery alongside major setbacks; the sequential revenue improvement and cost-cutting plan offer possible offsets, but do not erase the weak quarterly results. Article: Organogenesis Earnings Call Signals Recovery Amid Major Setbacks
• Negative Sentiment: Organogenesis reported a third-quarter loss of $0.25 per share, wider than the $0.18 loss analysts expected. Revenue of $45.46 million also missed the $52.10 million consensus estimate, raising concerns about near-term performance. Article: Organogenesis Reports Third Quarter 2026 Financial Results

About Organogenesis

Organogenesis Holdings Inc is a biotechnology company that develops, manufactures and commercializes products intended to support tissue regeneration and wound healing. The company serves the advanced wound care and surgical and sports medicine markets, with a focus on therapies that help manage complex wounds and support the repair of damaged tissue.

Its product portfolio includes bioengineered skin substitutes and other biologic products, such as Apligraf, Dermagraft, NuShield, Affinity and NuCel.